(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 68.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Syndax Pharmaceuticals's revenue in 2025 is $111,551,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2025 to be $15,160,555,192, with the lowest SNDX revenue forecast at $13,065,907,597, and the highest SNDX revenue forecast at $17,705,421,649. On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $32,586,980,211, with the lowest SNDX revenue forecast at $14,284,453,625, and the highest SNDX revenue forecast at $43,300,972,292.
In 2027, SNDX is forecast to generate $45,313,050,791 in revenue, with the lowest revenue forecast at $19,667,089,543 and the highest revenue forecast at $66,177,826,802.